Evaluation of mono- and dibenzoyl esters of dopamine as potential pro-drugs for dopamine in the central nervous system
- 34 Downloads
In this study, two ester pro-drugs of dopamine (DA) were synthesized and evaluated. These derivatives were the monobenzoyl (MBDA) and dibenzoyl (DBDA) esters of DA. MBDA was 300-fold and DBDA was 20,000-fold more lipophilic than DA itself. The half-lives of hydrolysis for MBDA and DBDA at physiologic pH and temperature were 15 and 420 min respectively. These compounds were radiolabelled and their uptake into brain measured. 14C-DBDA penetrated the brain rapidly; 0.28% of the dose injected was taken up per gram of brain tissue at 5 min. However DBDA did not produce measurable increases in DA levels in the brain. 14C-MBDA was found not to penetrate the brain. However, when MBDA was administered intracerebroventricularly (i.c.v.) to rats, it caused DOPAC levels to increase significantly both in the striatum and in the rest of the brain. The increase in the amount of DOPAC measured in the striatum was 3 to 10-fold greater than that seen in the rest of the brain. In rats that were pretreated with the MAO inhibitor, pargyline, MBDA given i.c.v. caused increases in DA levels in both the striatum and in the rest of the brain. The increased DA levels in striatum were considerably greater than those seen in the rest of the brain. From these results, it is inferred that MBDA is being hydrolyzed in vivo in the brain to form DA which is then taken up into dopaminergic neurons. Given this, it seems likely that an ester pro-drug of DA can be obtained that will have sufficient lipophilicity to penetrate the brain as well as a rate of hydrolysis that will produce increases in DA in the brain.
Key wordsPro-drug Monobenzoyldopamine Dibenzoyldopamine Lipophilicity Hydrolysis
Unable to display preview. Download preview PDF.
- Bianchine JR (1980) Drugs for Parkinson's disease. In: Gilman AG, Goodman LS, Gilman A (eds) The Pharmacological Basis of Therapeutics. Macmillan, New York, pp 475–487Google Scholar
- Capon B, Ghosh BC (1966) The mechanism of the hydrolysis of phenyl salicylate and catechol monobenzoate in the presence and absence of borate ions. J Chem Soc (B) 473–478Google Scholar
- Casagrande C, Ferrari G (1973) 3,4-O-Diacyl derivatives of dopamine. Il Farmaco 28:143–148Google Scholar
- Casagrande C, Santangelo F, Saini C, Doggi F, Gerli F, Cerri O (1986) Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites. Arzneim-Forsch (Drug Res) 36:291–303Google Scholar
- Dischino DD, Welch MJ, Kilbourn MR, Raichle ME (1983) Relationship between lipophilicity and brain extraction of C-11 labeled radiopharmaceuticals. J Nucl Med 24:1030–1038Google Scholar
- Gardner CR, Alexander J (1985) Prodrug approaches to drug targeting: Past accomplishments and future potential. In: Buri P, Gumman A (eds) Drug Targeting. Elsevier, Amsterdam, pp 145–164Google Scholar
- Marrel C, Boss G, Testa B, van de Waterbeemd H, Cooper D, Jenner P, Marsden CD (1985) l-Dopa esters as potential prodrugs. Eur J Med Chem 20:467–470Google Scholar
- Westerink BHC, Mulder TBA (1981) Determination of picomole amounts of dopamine, noradrenaline, 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid in nervous tissue after one-step purification on Sephadex G10, using high-performance liquid chromatography with a novel type of electrochemical detection. J Neurochem 36:1449–1462CrossRefGoogle Scholar